secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2026-05-15T20:07:33+00:00
Accession:  0001493152-26-023758
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q1 net loss down 27% YoY; FDA clears LP-300 trial amendments, IND for pediatric CNS cancer
--------------------------------------------------------------------------------

- Net loss of $3.3M ($0.30/sh) vs $4.5M ($0.42/sh) in Q1 2025, a 27% reduction.
- R&D expenses fell 47% YoY to $1.7M; cash & marketable securities $6.3M at March 31, plus $4.4M May financing.
- Successful FDA Type C meeting for LP-300 HARMONIC trial; protocol amended to focus on EGFR exon 21 L858R mutation as single-arm study.
- IND cleared for Starlight Therapeutics' STAR-001 pediatric CNS cancer trial (ATRT); Rare Pediatric Disease Designations.
- Launched withZeta.ai commercial AI platform; announced plan to spin it into independent entity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/0001493152-26-023758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315226023758/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-023758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer